Reckitt Benckiser Group PLC
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Portnoy Law is initiating an investigation into Reckitt in light of recent events that have led to a significant decline in the company’s stock value. This follows an Illinois jury’s decision to award $60 million in damages to the plaintiff in a lawsuit involving Reckitt’s Enfamil baby formula. The verdict was announced on behalf of the mother of a premature infant who tragically passed away from an intestinal disease, allegedly linked to the use of Enfamil.
In response to the verdict, shares of Reckitt Benckiser, a leading consumer goods conglomerate known for brands such as Lysol, Dettol, and Strepsils, experienced a drastic drop of more than 15%, marking the lowest point in a decade for the London-listed shares. This severe market reaction reflects growing investor apprehension regarding the potential financial impact of numerous pending lawsuits claiming that Enfamil and other baby formulas, including Abbott Laboratories’ Similac, are responsible for a fatal disease primarily affecting premature infants.
The investigation aims to determine whether Reckitt Benckiser and its executives violated securities laws by failing to disclose material information to shareholders about the safety of its products and the associated legal risks.
